Clearwater Cardiovascular Consultants

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease8 trials
• Heart failure4 trials
• Peripheral artery disease3 trials
• High blood pressure2 trials
• Atrial fibrillation1 trial
• Chronic kidney disease1 trial
• Familial hypercholesterolaemia1 trial
• Stroke1 trial
• Type 2 diabetes1 trial

Phase

• Phase 35 trials
• Phase 42 trials

Status

• Completed7 trials
• Active, not recruiting6 trials
• Recruiting3 trials
• Enrolling by invitation1 trial

Lead sponsor

• Amgen2 trials
• Janssen Research & Development, LLC2 trials
• Boehringer Ingelheim1 trial
• Boston Scientific Corporation1 trial
• Concept Medical Inc.1 trial
• and 10 more

Running trials

• Enrolling by invitation

  Novel On-body Evaluation of Cardiac Health for Oncology

  NCT07158450· Skribe Medical· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

  NCT06909565· Phase 4· Duke University· Source

  Contact: Carolyn Rembish

• Recruiting

  Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

  NCT06182397· Concept Medical Inc.· Source

  Contact: Brianna Landon

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

  Contact: Steven J. Evans, MD

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

  NCT05284747· Phase 4· Amgen· Source

• Active, not recruiting

  SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

  NCT05198674· Medtronic Vascular· Source

• Active, not recruiting

  Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

  NCT04562532· Shanghai MicroPort Medical (Group) Co., Ltd.· Source

• Active, not recruiting

  Personalized Therapy Study - Attain Stability Quad Post-Approval Study

  NCT04024943· Medtronic· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease2 recruiting
• Familial hypercholesterolaemia1 recruiting
• Heart failure1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

  NCT03875651· Boston Scientific Corporation· Source

• Completed

  Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

  NCT03241459· SurModics, Inc.· Source

• Completed

  PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

  NCT03168776· Sino Medical Sciences Technology Inc.· Source